PLX: Protalix BioTherapeutics Inc. Market Capitalization-to-Revenue Ratio

Corporate company logo of Protalix BioTherapeutics Inc. (PLX)

The historical P/S chart allows for a valuation of Protalix BioTherapeutics relative to sales, where 2.90 indicates the value of this parameter. FDA patents and the costly compliance of ProCellEx laboratories create a defensive barrier for the company. Growth is driven by the success of the drug Elfabrio, licensing payments, and new clinical trials. An eco-friendly approach to protein synthesis in plants minimizes toxic waste and energy costs.

Price-to-Revenue Ratio: protalix.com (PLX) for 07/04/2022 - 11/13/2026

Analytical breakdowns for Protalix (PLX)

- share price and expert price forecast:
Quote Chart protalix.com|PLX - Analyst Consensus Forecast
- market capitalization information:
Market Value Protalix|PLX - Enterprise Value
- book capitalization indicators:
Book Value per Share Protalix BioTherapeutics|PLX - Company Book Value|Market Value to Book Value protalix.com|PLX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Protalix BioTherapeutics|PLX - Long-Term Debt to Capital|Short-Term Debt to Capital Protalix BioTherapeutics, Inc|PLX - Company Debts|Debts to Book Capitalization Ratio Protalix|PLX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Protalix BioTherapeutics|Immediate Liquidity protalix.com
- company profitability and valuation multiples indicators:
PLX - Net Income|Future Net Profit Protalix BioTherapeutics|PLX - P/E Multiple|Forward P/E Multiple Protalix BioTherapeutics Inc.|PLX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix|PLX - Operating profit EBITDA|Net earnings per share for the last four quarters Protalix BioTherapeutics|PLX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months protalix.com|PLX - Net earnings per share growth this year|Expected earnings per share trend next year Protalix BioTherapeutics
- total revenue and sales volume data:
PLX - Revenue and Sales Volume|Company Projected Revenue protalix.com|PLX - P/S Multiple|Market Cap to Expected Sales Ratio Protalix
Fundamental company analysis:protalix.com - PLX
Original product of Protalix

The P/S ratio compares market capitalization to annual revenue, reflecting the premium the market is willing to pay per unit of company income. This metric filters out speculative noise, which is critical for Protalix BioTherapeutics (PLX), as its commercial expansion depends on external partners; therefore, analyzing the company's normalized P/S helps avoid buying at peaks and protects capital from drawdowns.

Competitors of Protalix BioTherapeutics

VRTX: Price-to-Sales Ratio|P/S Multiple ALNY (Alnylam)|Market Capitalization-to-Revenue Ratio INSM|United Therapeutics Corp. - P/S Multiple|BMRN - P/S Multiple|BridgeBio Pharma, Inc. (BBIO) - Price-to-Revenue Ratio|BGM Group - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cogent Biosciences, Inc.|Market Cap to Revenue Xeris Biopharma Holdings, Inc. (XERS)|P/S Multiple KROS|P/S Multiple Arcturus Corp (ARCT)|Price-to-Revenue Ratio Eton Pharmaceuticals ETON|KMDA (kamada.com) - Price-to-Sales Ratio|FULC - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ABEO (Abeona Therapeutics)|mereobiopharma.com (MREO) - Price-to-Revenue Ratio|Price to Sales Pliant Therapeutics, Inc. (PLRX)|Market Cap to Revenue APLT|RNTX (aileronrx.com) - Market Cap to Sales Volume|P/S Multiple GELS|P/S Multiple aytubio.com (AYTU)|Price-to-Revenue Ratio Chemomab Therapeutics Ltd. CMMB|SRx Health Solutions Inc - Price-to-Revenue Ratio|Polyrizon Ltd. - P/S Multiple|Price-to-Revenue Coefficient Aeterna Zentaris AEZS|CYTH (Cyclo Therapeutics, Inc.) - Market Cap to Revenue|Market Cap to Revenue Ratio INZY|Market Cap to Revenue RPHM|CSCI: Market Capitalization-to-Revenue Ratio